|
Improving the dosing cycle of biopharmaceuticals is very much an agenda item for many drug companies. One route showing great promise is the delivery of depot injections comprising bio-particles containing the active drug which is released slowly into the body from the site of injection. However, depot formulations of biologics present two important challenges. The first is sterilization. The second is the stability of the drug at body temperature or 37°C. Arecor offers solutions to both problems.
Arestat-R™ permits the terminal sterilization of many biopharmaceuticals and their carrier molecules without degradation and Arestat-T™ provides for stability of the drug at body temperature.
A combination of Arestat-R™ and Arestat-T™ can readily be applied to the development of depot formulations of recombinant proteins. Efforts are underway to develop depot formulations of Human Growth Hormone and Human Insulin. |
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
